Merus (NASDAQ:MRUS) Stock Rating Reaffirmed by Needham & Company LLC

by · The Cerbat Gem

Needham & Company LLC reissued their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a research note published on Thursday morning, Benzinga reports. Needham & Company LLC currently has a $66.00 price target on the biotechnology company’s stock.

A number of other research firms have also recently issued reports on MRUS. Truist Financial started coverage on Merus in a report on Thursday, March 28th. They issued a buy rating and a $69.00 price target for the company. BMO Capital Markets lifted their price target on Merus from $49.00 to $58.00 and gave the company an outperform rating in a report on Thursday, February 29th. Stifel Nicolaus lifted their price target on Merus from $40.00 to $65.00 and gave the company a buy rating in a report on Thursday, February 29th. StockNews.com cut Merus from a hold rating to a sell rating in a report on Monday, March 4th. Finally, HC Wainwright lifted their price target on Merus from $48.00 to $65.00 and gave the company a buy rating in a report on Thursday, February 29th. One analyst has rated the stock with a sell rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of Moderate Buy and an average target price of $53.64.

Check Out Our Latest Stock Report on MRUS

Merus Price Performance

Shares of NASDAQ MRUS opened at $41.85 on Thursday. The business has a fifty day moving average of $44.85 and a two-hundred day moving average of $32.56. Merus has a 52-week low of $18.21 and a 52-week high of $52.03.

Merus (NASDAQ:MRUS – Get Free Report) last issued its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.38). Merus had a negative net margin of 352.56% and a negative return on equity of 50.61%. The company had revenue of $8.94 million for the quarter, compared to the consensus estimate of $10.43 million. As a group, equities analysts forecast that Merus will post -3.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Merus

Institutional investors and hedge funds have recently modified their holdings of the business. Quadrant Capital Group LLC grew its position in shares of Merus by 37.7% in the 4th quarter. Quadrant Capital Group LLC now owns 1,253 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 343 shares during the period. BluePath Capital Management LLC acquired a new position in shares of Merus in the 3rd quarter valued at approximately $33,000. China Universal Asset Management Co. Ltd. grew its position in shares of Merus by 142.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,477 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 867 shares during the period. JPMorgan Chase & Co. grew its position in shares of Merus by 871.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,564 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 1,403 shares during the period. Finally, Coppell Advisory Solutions LLC bought a new stake in Merus in the 2nd quarter valued at approximately $47,000. 96.14% of the stock is currently owned by institutional investors and hedge funds.

Merus Company Profile

(Get Free Report)

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

Further Reading